Treatment News : New Studies Under Way of Sangamo's Possible 'Functional Cure' Gene Therapy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 10, 2012

New Studies Under Way of Sangamo's Possible 'Functional Cure' Gene Therapy

Sangamo BioSciences has begun new clinical studies of its promising gene therapy SB-728-T, a potential “functional cure” for HIV infection, according to a January 9 announcement by the company. 

SB-728-T is a zinc finger DNA-binding protein transcription factor (ZFP TF). It disrupts the gene responsible for making CCR5 co-receptors on the surface of CD4 cells, to which HIV bonds. When CD4 cells can’t produce functional co-receptors, it is much harder for HIV to infect them.

The aim of SB-728-T therapy is to grow a new population of CD4 cells that are resistant to HIV infection, and thus make antiretroviral (ARV) therapy unnecessary.

The rationale for using SB-728-T comes from the case of Timothy Brown, an HIV-positive man with leukemia who received two stem cell transplants from a donor who inherited two mutated CCR5 genes (CCR5 delta32), from his father and mother, and was genetically unable to produce CD4 cells that carry functional CCR5 co-receptors. Such individuals rarely become infected with HIV. And in cases where only one mutated CCR5 gene is inherited, HIV infection can occur, but the disease tends to progress slowly.

In Brown’s case, not only did the stem cell therapy cure his cancer, but it also appears to have cured his HIV infection. All efforts to locate HIV in the man’s body have been unsuccessful.

Sangamo is hoping that treating a person’s own stem cells with SB-728-T and then reinfusing them will, over time, replace HIV-susceptible cells with HIV-resistant CD4s and reduce the need for continuous antiretroviral therapy. Though such genetic modifications of stem cells have not yet been tried, the company is exploring the effects of SB-728-T on patients' own CD4 cells.

“We are delighted to be able to open these two important clinical studies ahead of schedule,” said Geoff Nichol, MB ChB, Sangamo’s executive vice president of research and development. “Data from earlier Phase 1 trials demonstrated a statistically significant relationship between the number of circulating [CD4s] in which both CCR5 genes are modified and the reduction in HIV viral load in infected subjects during an interruption of antiretroviral therapy. Both of these new [Phase II] clinical trials are specifically designed to confirm and further investigate these findings.”

The new studies employ two approaches to increase the number of infused CD4 cells in which both CCR5 gene copies are modified using SB-728-T. The first study, an extension of an ongoing trial (SB-728-902), will explore the effect of SB-728-T treatment on viral load in people living with HIV who inherited one CCR5 delta32 genetic mutation. The second study (SB-728-1101), involving people living with HIV without the CCR5 delta32 mutation, involves a pre-infusion course of chemotherapy to significantly enhance the proliferation of the gene-modified CD4 cells in the body.

In the extension of the SB-728-902 trial, up to 20 HIV-positive volunteers with one copy of the CCR5 delta32 deletion who are currently receiving ARV therapy will be enrolled and will receive a single intravenous infusion of 5 billion to 30 billion SB-728-T-modifed CD4 cells. Two months later, these volunteers will undergo a 16-week ARV treatment interruption. HIV treatment will be restarted if the patients’ CD4 cells drop below 350 or if their viral loads are above 100,000 for three weeks in a row. After 16 weeks, only those who maintain undetectable viral loads will be permitted to remain off therapy. 

The SB-728-1101 trial will mainly evaluate the safety and tolerability of Cytoxan (cyclophosphamide) chemotherapy, administered one day before being infused with SB-728-T-modified CD4 cells. Cytoxan is a chemotherapeutic drug used to temporarily reduce the numbers of CD4 cells in the body, which then rapidly repopulate once the drug is discontinued.

Chemotherapeutic “conditioning” therapy has been used to enhance engraftment of cells in the treatment of cancer and for numerous autoimmune diseases. The drug has been previously used in people living with HIV, with studies demonstrating that while the drug does reduce CD4s, it does not have a long-term effect on CD4 cell counts.

In addition to safety, the study will evaluate the effect of Cytoxan—administered intravenously at a dose of either 200 milligrams (mg), 500 mg or 1,000 mg—on SB-728-T engraftment, the effect of SB-728-T treatment on viral load following ARV therapy interruption, the change in CD4 cell counts and the long-term persistence of SB-728-T. At least nine people living with HIV receiving ARV therapy will be enrolled in the study.

Six weeks after receiving the infusion of SB-728-T-modifed CD4 cells, patients with CD4 cell counts of at least 500 will undergo a 16-week treatment interruption. Therapy will be reinstituted in the event the CD4 cell count falls below 500 or viral load exceeds 100,000 for three weeks.

To learn more about the extension of the SB-728-902 study, including enrollment information, click here (look for "Cohort 5" references). Recruitment information for SB-728-1101 is not yet available.

Search: SB-728-T, sangamo, ZFN, zinc finger nuclease, phase II, clinical trials, studies


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 15 (of 24 total)     next > >>

frank, witbank, south Africa, 2013-01-12 12:04:16
let us know if the trial went successfully. We've had enough about this deadly monster diseases. May GOD bless u..

landy, , 2012-10-08 12:32:25
I am a Chinese person infected in Aug 2012. if you need a new infection asian to trial. Please contact me. I do would like to be included.

chad, houston, 2012-06-03 22:53:48
I was approached by my Dr to take part in this study. I have been + since 2007. I have been undetectable for several years and my T-cells are 1800+. I Do not do studies usually. As a nurse and after studying this one i could not say no. I hope by doing this study they learn what they need to learn to cure us all. Gods love to you all.

kimi, , 2012-03-09 18:45:41
I am hiv neg, my husband is hiv pos for 20+ years. I have a genetic eye disease, thus a mutated gene. Perhaps the ccr5 gene. I want to be included in the trials. Pls contact me. Thank you

john schatz, Reno, 2012-03-06 14:31:07
As I said in the early 80's this was the answer a single cell receptoor gene cannot be infected because the HIV cell requires 2 receptors to attach to sb-7280_T and other combos of numbers great stride to give persons without ccr5 cell a chance to beat AIDS I also kow of another curre if possible requires money n. Time to research back to previous ccr5 gene happned due to survivors of blubonic plague got this gene why we don't know yet...

anyone, charleston, 2012-03-03 20:00:39
I feel that from what I've learned that hiv is a genetic disease and thats the best way to cure it so if this isn't the cure then what else is cause i doubt if a vaccine will be out anytime soon that is gonna work only time will tell which most of us don't have. Just have to say a prayer that sangamo feels just a bit the way infected ppl feel and try to push this into production if it really works.

wes, San Diego, Ca., 2012-02-12 22:52:15
Currently going on 30 years now living with HIV. I have tryed contacting Sangamo several times, and even there top research person involved in this therapy. Still no answer, tired of the BS, I have forwarded tis info and the article with weblinks to 60 Minutes and Brian Williams. Maybe the press will bring this forward! the 30.6 million people infected with this virus have a right to know the facts from the specific persons involved.

Colin, Salem, Oregon, 2012-02-09 02:36:49
Someday soon we'll have our cure.

Eddy, New York City, 2012-01-30 23:46:20
So we have to wait for those that have inherited the CCR5 delta gene, that are infected with HIV for phase 2 to start enrollment??? Horse shiv!!! It's unjust to those that are willing to start chemo with sb728t! Wicked and cruel! Let's start phase 2! Yesterday, not in 2020!!!

Jesus, Dallas, 2012-01-25 06:06:35
I pray this is the cure! I was just diagnosed in dec 2011 and it would be amazing to avoid all meds. I have faith in god this will work. To be honest, i never knew so many advances had been made on hiv/aids treatment until i got infected

staying hopeful, anywhere usa, 2012-01-21 14:59:30
I pray that there will be some significant progress in this Sangamo Hiv research, this illness has caused enough pain to so many lives I think it's time for a change in the worldfor everyone effected by this terrible disease God Bless ALL Hiv infected and family's dealing with this illness

Alonso, iquique,chile, 2012-01-19 15:20:05
hello! I'm Chilean and HIV positive since 2011. I wonder how I can participate in the tests. Like many, I have high hopes for this treatment. greetings and best of luck to all!

AS, Zomba, Malawi, 2012-01-19 03:22:26
Is it possible to do this research in Malawi? I am interested if they can Put me on Sangamo research trial

Patrick, Houston, 2012-01-18 15:12:00
How and where is the Sangamo's Possible 'Functional Cure' Gene Therapy being done and where can i sign up for it? I have done several studies in the past and alot of research and anything that might be concidered a cure I am more than intrested in partisipating in!

mekonen assefa, ethiopia, 2012-01-18 13:39:20
I am hiv posetive so i am volountry to participate in the study

comments 1 - 15 (of 24 total)     next > >>


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    RyGuy00
    New York
    New York


    hollywoodvers1
    Los Angeles
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.